Bioventus Affirms FY2026 Adj EPS Guidance of $0.75-$0.79 vs $0.78 Est; Affirms FY2026 Sales Guidance of $600.000M-$610.000M vs $605.756M Est

Bioventus (NASDAQ: BVS ) affirms FY2026 Adj EPS guidance from $0.75-$0.79 to $0.75-$0.79 vs $0.78 analyst estimate. Affirms FY2026 sales outlook from $600.000 million-$610.000 million to $600.000 million-$610.000 million vs $605.756 million estimate.